Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial
- Salvarani, Carlo
- Dolci, Giovanni
- Massari, Marco
- Merlo, Domenico Franco
- Cavuto, Silvio
- Savoldi, Luisa
- Bruzzi, Paolo
- Boni, Fabrizio
- Braglia, Luca
- Turrà, Caterina
- Ballerini, Pier Ferruccio
- Sciascia, Roberto
- Zammarchi, Lorenzo
- Para, Ombretta
- Scotton, Pier Giorgio
- Inojosa, Walter Omar
- Ravagnani, Viviana
- Salerno, Nicola Duccio
- Sainaghi, Pier Paolo
- Brignone, Alessandro
- Codeluppi, Mauro
- Teopompi, Elisabetta
- Milesi, Maurizio
- Bertomoro, Perla
- Claudio, Norbiato
- Salio, Mario
- Falcone, Marco
- Cenderello, Giovanni
- Donghi, Lorenzo
- Del Bono, Valerio
- Colombelli, Paolo Luigi
- Angheben, Andrea
- Passaro, Angelina
- Secondo, Giovanni
- Pascale, Renato
- Piazza, Ilaria
- Facciolongo, Nicola
- Costantini, Massimo
Publication date
January 2021
DOI Publisher
American Medical Association (AMA) Language
EnglishAbstract
The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile
Add to ORKG